T S Bailey, J Pettus, R Roussel, W Schmider, M Maroccia, N Nassr, O Klein, G B Bolli, R Dahmen. Diabetes Metab 2018
Times Cited: 58
Times Cited: 58
Times Cited
Times Co-cited
Similarity
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr. Diabetes Obes Metab 2017
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr. Diabetes Obes Metab 2017
60
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, Anne Lehmann, Thomas Jax, Tim Heise. Diabetes Care 2015
Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, Anne Lehmann, Thomas Jax, Tim Heise. Diabetes Care 2015
55
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
55
Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
Richard M Bergenstal, Timothy S Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J Ahmann. Diabetes Care 2017
Richard M Bergenstal, Timothy S Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J Ahmann. Diabetes Care 2017
39
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
32
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
G B Bolli, M C Riddle, R M Bergenstal, M Ziemen, K Sestakauskas, H Goyeau, P D Home. Diabetes Obes Metab 2015
G B Bolli, M C Riddle, R M Bergenstal, M Ziemen, K Sestakauskas, H Goyeau, P D Home. Diabetes Obes Metab 2015
31
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Matthew C Riddle, Geremia B Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, Philip D Home. Diabetes Care 2014
Matthew C Riddle, Geremia B Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, Philip D Home. Diabetes Care 2014
31
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
31
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
T Heise, L Hermanski, L Nosek, A Feldman, S Rasmussen, H Haahr. Diabetes Obes Metab 2012
T Heise, L Hermanski, L Nosek, A Feldman, S Rasmussen, H Haahr. Diabetes Obes Metab 2012
31
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
R Ritzel, R Roussel, G B Bolli, L Vinet, C Brulle-Wohlhueter, S Glezer, H Yki-Järvinen. Diabetes Obes Metab 2015
R Ritzel, R Roussel, G B Bolli, L Vinet, C Brulle-Wohlhueter, S Glezer, H Yki-Järvinen. Diabetes Obes Metab 2015
29
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
29
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
27
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Tim Heise, Ulrike Hövelmann, Leszek Nosek, Lidia Hermanski, Susanne G Bøttcher, Hanne Haahr. Expert Opin Drug Metab Toxicol 2015
Tim Heise, Ulrike Hövelmann, Leszek Nosek, Lidia Hermanski, Susanne G Bøttcher, Hanne Haahr. Expert Opin Drug Metab Toxicol 2015
27
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
24
Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
22
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
22
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
R H A Becker, I Nowotny, L Teichert, K Bergmann, C Kapitza. Diabetes Obes Metab 2015
R H A Becker, I Nowotny, L Teichert, K Bergmann, C Kapitza. Diabetes Obes Metab 2015
22
Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Stephen C L Gough, Anuj Bhargava, Rajeev Jain, Henriette Mersebach, Søren Rasmussen, Richard M Bergenstal. Diabetes Care 2013
Stephen C L Gough, Anuj Bhargava, Rajeev Jain, Henriette Mersebach, Søren Rasmussen, Richard M Bergenstal. Diabetes Care 2013
20
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C Riddle. Diabetes Care 2015
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C Riddle. Diabetes Care 2015
20
A review of the pharmacological properties of insulin degludec and their clinical relevance.
Hanne Haahr, Tim Heise. Clin Pharmacokinet 2014
Hanne Haahr, Tim Heise. Clin Pharmacokinet 2014
18
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.
Tim Heise, Chantal Mathieu. Diabetes Obes Metab 2017
Tim Heise, Chantal Mathieu. Diabetes Obes Metab 2017
18
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles.
Yuji Kawaguchi, Jun Sawa, Noriko Sakuma, Yasuro Kumeda. J Diabetes Investig 2019
Yuji Kawaguchi, Jun Sawa, Noriko Sakuma, Yasuro Kumeda. J Diabetes Investig 2019
47
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
17
A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Stefan Korsatko, Sigrid Deller, Gerd Koehler, Julia K Mader, Katharina Neubauer, Charlotte L Adrian, Henrik Thomsen, Hanne Haahr, Thomas R Pieber. Clin Drug Investig 2013
Stefan Korsatko, Sigrid Deller, Gerd Koehler, Julia K Mader, Katharina Neubauer, Charlotte L Adrian, Henrik Thomsen, Hanne Haahr, Thomas R Pieber. Clin Drug Investig 2013
17
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Fang Liz Zhou, Fen Ye, Paulos Berhanu, Vineet E Gupta, Rishab A Gupta, Jennifer Sung, Jukka Westerbacka, Timothy S Bailey, Lawrence Blonde. Diabetes Obes Metab 2018
Fang Liz Zhou, Fen Ye, Paulos Berhanu, Vineet E Gupta, Rishab A Gupta, Jennifer Sung, Jukka Westerbacka, Timothy S Bailey, Lawrence Blonde. Diabetes Obes Metab 2018
20
Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
R Roussel, R Ritzel, E Boëlle-Le Corfec, B Balkau, J Rosenstock. Diabetes Metab 2018
R Roussel, R Ritzel, E Boëlle-Le Corfec, B Balkau, J Rosenstock. Diabetes Metab 2018
38
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
Y Terauchi, M Koyama, X Cheng, Y Takahashi, M C Riddle, G B Bolli, T Hirose. Diabetes Obes Metab 2016
Y Terauchi, M Koyama, X Cheng, Y Takahashi, M C Riddle, G B Bolli, T Hirose. Diabetes Obes Metab 2016
15
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Luigi Meneghini, Stephen L Atkin, Stephen C L Gough, Itamar Raz, Lawrence Blonde, Marina Shestakova, Stephen Bain, Thue Johansen, Kamilla Begtrup, Kåre I Birkeland. Diabetes Care 2013
Luigi Meneghini, Stephen L Atkin, Stephen C L Gough, Itamar Raz, Lawrence Blonde, Marina Shestakova, Stephen Bain, Thue Johansen, Kamilla Begtrup, Kåre I Birkeland. Diabetes Care 2013
15
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Tim Heise, Leszek Nosek, Birgitte Biilmann Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, Eberhard Draeger. Diabetes 2004
Tim Heise, Leszek Nosek, Birgitte Biilmann Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, Eberhard Draeger. Diabetes 2004
15
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N Engl J Med 1993
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N Engl J Med 1993
15
Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
15
Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study.
M Peyrot, A H Barnett, L F Meneghini, P-M Schumm-Draeger. Diabet Med 2012
M Peyrot, A H Barnett, L F Meneghini, P-M Schumm-Draeger. Diabet Med 2012
15
International Consensus on Use of Continuous Glucose Monitoring.
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
15
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
13
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sean D Sullivan, Timothy S Bailey, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Ronald Preblick, Jukka Westerbacka, Rishab A Gupta, Lawrence Blonde. Diabetes Obes Metab 2018
Sean D Sullivan, Timothy S Bailey, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Ronald Preblick, Jukka Westerbacka, Rishab A Gupta, Lawrence Blonde. Diabetes Obes Metab 2018
18
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
Robert Ritzel, Ronan Roussel, Andrea Giaccari, Jiten Vora, Claire Brulle-Wohlhueter, Hannele Yki-Järvinen. Diabetes Obes Metab 2018
Robert Ritzel, Ronan Roussel, Andrea Giaccari, Jiten Vora, Claire Brulle-Wohlhueter, Hannele Yki-Järvinen. Diabetes Obes Metab 2018
17
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
13
Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
Tim Heise, Kadriye Kaplan, Hanne L Haahr. J Diabetes Sci Technol 2018
Tim Heise, Kadriye Kaplan, Hanne L Haahr. J Diabetes Sci Technol 2018
38
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
13
Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study.
Mizuho Yamabe, Mami Kuroda, Yasuyo Hirosawa, Hiromi Kamino, Haruya Ohno, Masayasu Yoneda. J Diabetes Investig 2019
Mizuho Yamabe, Mami Kuroda, Yasuyo Hirosawa, Hiromi Kamino, Haruya Ohno, Masayasu Yoneda. J Diabetes Investig 2019
50
Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
Francesca Porcellati, Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Gianluca Curti, Geremia B Bolli, Carmine G Fanelli. Diabetes Care 2019
Francesca Porcellati, Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Gianluca Curti, Geremia B Bolli, Carmine G Fanelli. Diabetes Care 2019
40
Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Athena Philis-Tsimikas, David C Klonoff, Kamlesh Khunti, Harpreet S Bajaj, Lawrence A Leiter, Melissa V Hansen, Lone N Troelsen, Steen Ladelund, Simon Heller, Thomas R Pieber. Diabetologia 2020
Athena Philis-Tsimikas, David C Klonoff, Kamlesh Khunti, Harpreet S Bajaj, Lawrence A Leiter, Melissa V Hansen, Lone N Troelsen, Steen Ladelund, Simon Heller, Thomas R Pieber. Diabetologia 2020
27
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
M Lepore, S Pampanelli, C Fanelli, F Porcellati, L Bartocci, A Di Vincenzo, C Cordoni, E Costa, P Brunetti, G B Bolli. Diabetes 2000
M Lepore, S Pampanelli, C Fanelli, F Porcellati, L Bartocci, A Di Vincenzo, C Cordoni, E Costa, P Brunetti, G B Bolli. Diabetes 2000
12
Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.
Jiten Vora, Torsten Christensen, Azhar Rana, Steve C Bain. Diabetes Ther 2014
Jiten Vora, Torsten Christensen, Azhar Rana, Steve C Bain. Diabetes Ther 2014
12
12
Identification of barriers to insulin therapy and approaches to overcoming them.
David Russell-Jones, Frans Pouwer, Kamlesh Khunti. Diabetes Obes Metab 2018
David Russell-Jones, Frans Pouwer, Kamlesh Khunti. Diabetes Obes Metab 2018
12
Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.
Kamlesh Khunti, Michael L Wolden, Brian Larsen Thorsted, Marc Andersen, Melanie J Davies. Diabetes Care 2013
Kamlesh Khunti, Michael L Wolden, Brian Larsen Thorsted, Marc Andersen, Melanie J Davies. Diabetes Care 2013
12
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
H Yki-Järvinen, R M Bergenstal, G B Bolli, M Ziemen, M Wardecki, I Muehlen-Bartmer, M Maroccia, M C Riddle. Diabetes Obes Metab 2015
H Yki-Järvinen, R M Bergenstal, G B Bolli, M Ziemen, M Wardecki, I Muehlen-Bartmer, M Maroccia, M C Riddle. Diabetes Obes Metab 2015
12
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
M Matsuhisa, M Koyama, X Cheng, Y Takahashi, M C Riddle, G B Bolli, T Hirose. Diabetes Obes Metab 2016
M Matsuhisa, M Koyama, X Cheng, Y Takahashi, M C Riddle, G B Bolli, T Hirose. Diabetes Obes Metab 2016
12
A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes.
Joseph Tibaldi, Martin Hadley-Brown, Andreas Liebl, Steffen Haldrup, Viktor Sandberg, Michael L Wolden, Helena W Rodbard. Diabetes Obes Metab 2019
Joseph Tibaldi, Martin Hadley-Brown, Andreas Liebl, Steffen Haldrup, Viktor Sandberg, Michael L Wolden, Helena W Rodbard. Diabetes Obes Metab 2019
29
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.